Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Salarius Pharmaceuticals
(NASDAQ:SLRX)
Intraday
$0.52
0.019
[3.79%]
After-Hours
$0.52
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.52
0.019
[3.79%]
At close: Apr 23
$0.52
0
[0.00%]
PreMarket: 5:49PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Salarius Pharmaceuticals Stock (NASDAQ:SLRX)
Salarius Pharmaceuticals Stock (NASDAQ: SLRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 27, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Mar 27, 2024, 12:31PM
Monday, March 25, 2024
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Mar 25, 2024, 2:44PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Mar 25, 2024, 9:05AM
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 25, 2024, 8:03AM
Salarius Pharmaceuticals shares are trading higher after the company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 25, 2024, 7:45AM
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
Avi Kapoor
-
Mar 25, 2024, 2:50AM
Friday, March 22, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Mar 22, 2024, 5:33PM
Salarius Pharmaceuticals shares are trading higher after the company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 22, 2024, 4:10PM
Salarius Pharmaceuticals Q4 2023 GAAP EPS $(0.22) Beats $(1.01) Estimate
Benzinga Newsdesk
-
Mar 22, 2024, 4:07PM
Thursday, February 22, 2024
Salarius Provides Update On Strategic Review Process And Plans To Support Ongoing Seclidemstat Clinical Trials By Further Reducing Expenses, Implementing A Series Of Cost-Savings Measures Designed To Extend Expected Cash Runway Into The First Half Of 2025
Benzinga Newsdesk
-
Feb 22, 2024, 8:05AM
Thursday, February 01, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Feb 1, 2024, 8:06AM
Wednesday, January 17, 2024
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Jan 17, 2024, 8:18AM
Tuesday, January 16, 2024
Salarius Pharmaceuticals Issued U.S. Patent No. 11,773,080 Titled "Deuterium-Enriched Isoindolinonyl-Azepanediones And Related Compounds And Methods Of Treating Medical Disorders Using Same"
Benzinga Newsdesk
-
Jan 16, 2024, 8:16AM
Wednesday, January 03, 2024
Investigator-Initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat In Combination With Azacitidine To Treat Hematologic Cancers Resumes Patient Enrollment
Benzinga Newsdesk
-
Jan 3, 2024, 8:44AM
Tuesday, November 07, 2023
Salarius Completes FDA Type B Meeting For Seclidemstat Ewing Sarcoma Development Program
Benzinga Newsdesk
-
Nov 7, 2023, 8:30AM
Monday, October 30, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Oct 30, 2023, 9:05AM
Friday, October 27, 2023
Salarius Pharmaceuticals 13D Filing Shows Elvin Lee Reported 6.09% Stake In Co As Of 23 October 2023
Benzinga Newsdesk
-
Oct 27, 2023, 4:04PM
Friday, October 06, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Oct 6, 2023, 5:31PM
Thursday, August 17, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Aug 17, 2023, 1:31PM
Friday, August 11, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Aug 11, 2023, 2:01PM
Salarius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results
Benzinga Newsdesk
-
Aug 11, 2023, 12:22PM
Late Thursday, Salarius Pharmaceuticals Announced Plans To Explore Strategic Alternatives And Implement Measures To Extend Resources, Including Laying Off 50% Of Its Staff
Benzinga Newsdesk
-
Aug 11, 2023, 6:24AM
Thursday, August 10, 2023
Salarius Pharmaceuticals Q2 EPS $(1.43) Misses $(1.30) Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 5:05PM
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Aug 10, 2023, 1:43PM
Wednesday, August 09, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Aug 9, 2023, 12:27PM
Tuesday, August 08, 2023
Salarius Pharmaceuticals Announces Plans To Explore Strategic Alternatives And Implement Measures To Extend Its Resources
Happy Mohamed
-
Aug 8, 2023, 5:59PM
Wednesday, July 26, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Jul 26, 2023, 12:18PM
Monday, July 24, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 24, 2023, 3:48PM
Tuesday, July 11, 2023
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jul 11, 2023, 1:26PM
Watching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Target
Happy Mohamed
-
Jul 11, 2023, 1:07PM
Salarius Pharmaceuticals Receives FDA Clearance Of SP-3164 Investigational New Drug Application To Begin A Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Benzinga Newsdesk
-
Jul 11, 2023, 8:35AM
Tuesday, May 30, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
May 30, 2023, 9:07AM
Friday, May 12, 2023
Salarius Pharmaceuticals Announces $6M Private Placement Of 3.6M Shares, Series A-1 Warrants To Purchase Up To 3.6M Shares And Series A-2 Warrants To Purchase Up To 3.6M Shares At A Purchase Price Of $1.65 Per Share
Benzinga Newsdesk
-
May 12, 2023, 8:09AM
Thursday, May 11, 2023
Recap: Salarius Pharmaceuticals Q1 Earnings
Benzinga Insights
-
May 11, 2023, 8:17AM
Salarius Pharmaceuticals Q1 EPS $(2.23) Beats $(2.59) Estimate; Cash And Cash Equivalents Of $9.3M Are Expected To Fund The Company's Planned Operations Through Q3 2023
Benzinga Newsdesk
-
May 11, 2023, 8:06AM
Tuesday, May 09, 2023
Watching Salarius Pharma; Zacks Small-Cap Research Sets $17 Price Valuation On Stock
Happy Mohamed
-
May 9, 2023, 11:25AM
FDA Removed Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Charles Gross
-
May 9, 2023, 8:02AM
Monday, May 01, 2023
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies With Its Targeted Protein Degrader SP-3164
Benzinga Newsdesk
-
May 1, 2023, 8:34AM
Thursday, April 20, 2023
Salarius Pharmaceuticals Presents Compelling Data In Two SP-3164 Targeted Protein Degrader Posters At The American Association For Cancer Research Annual Meeting
Benzinga Newsdesk
-
Apr 20, 2023, 8:47AM
Thursday, April 13, 2023
This Combination Therapy Could Help Change Cancer Treatment — Benzinga Looks Deeper Into Allarity Therapeutics' Trial, Including An Interview With An Oncology Expert
David Willey
-
Sponsored
Monday, March 27, 2023
Salarius Pharmaceuticals Q4 EPS $(2.83) Misses $(2.15) Estimate
Benzinga Newsdesk
-
Mar 27, 2023, 8:32AM
Thursday, February 16, 2023
Salarius Pharmaceuticals Receives $1.48M From Cancer Prevention And Research Institute Of Texas
Benzinga Newsdesk
-
Feb 16, 2023, 8:35AM
Friday, January 27, 2023
Salarius Pharmaceuticals Highlights Presentation Of SP-3164 Preclinical Data Inaugural Molecular Glue Drug Development Summit; Data Showed SP-3164 Activity In Non-Hodgkin's Lymphoma
Bill Haddad
-
Jan 27, 2023, 8:34AM
Friday, January 20, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jan 20, 2023, 12:31PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Jan 20, 2023, 8:05AM
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jan 20, 2023, 7:55AM
Thursday, January 19, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Jan 19, 2023, 4:30PM
Salarius Pharmaceuticals To Present SP-3164 Targeted Protein Degrader Preclinical Data At The Inaugural Molecular Glue Drug Development Summit
Benzinga Newsdesk
-
Jan 19, 2023, 8:44AM
Thursday, January 12, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jan 12, 2023, 12:31PM
Thursday, January 05, 2023
Salarius Pharmaceuticals shares are trading higher after the company announced issuance of a new U.S. patent for next-generation targeted protein degraders.
Benzinga Newsdesk
-
Jan 5, 2023, 8:33AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch